Shares of Antares Pharma (NASDAQ: ATRS) were up 11.8% at 3:12 p.m. EDT on Monday after the company announced a deal with Pfizer (NYSE: PFE) to develop a combination drug-device rescue pen.
Unfortunately, there aren't many details for investors to go on here. The device will use Antares' QuickShot Auto-Injector, but the drug Pfizer plans to put inside the device wasn't disclosed, so it's hard to know how many of the drug devices Pfizer could sell.
Of course, even if investors had that information, we still couldn't analyze Antares' potential benefit, since the economics of the deal weren't disclosed, either. Pfizer will pay Antares for the cost to manufacture the product plus a margin, as well as royalties on net sales. But there weren't any numbers associated with the potential payments.
Despite the lack of details, the deal with Pfizer is certainly an endorsement of Antares' QuickShot, which could result in additional companies partnering with Antares to develop drug-device combinations for easy injection of their medications. Whether that's worth a double-digit bump in the company's share price is debatable.
Antares is scheduled to release second-quarter earnings Tuesday morning. Management might give a little more color on the deal during the associated conference call, but given the lack of details in the press release, the company is likely sworn to secrecy by Pfizer. While that's annoying for investors now, it's likely a good long-term move to keep Pfizer's competitors from getting word of what it's developing.
10 stocks we like better than Antares Pharma
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Antares Pharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.